Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to document the preliminary antitumor activity of two
doses of NGR-hTNF administered either alone or in combination with doxorubicin in locally
advanced or metastatic soft-tissue sarcoma (STS) patients untreated or previously treated
with one or more prior systemic regimen.